In a multiple-ascending dose study in NAFLD subjects, about 20% of whom had biopsy-confirmed NASH, weekly or every-other-weekly administration of BIO89-100 for 12 weeks reduced serum triglycerides by 18–28%, reduced liver fat by 36–60%, and increased adiponectin by 23–61% relative to baseline (299). Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.